JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis

Key Takeaways JNJ secured EU approval for Imaavy as an add-on therapy for generalized myasthenia gravis.Phase III and II/III studies showed Imaavy plus standard care delivered sustained disease control.Imaavy was approved in the United States in April 2025 for treating generalized myasthenia gravis.Johnson & Johnson (JNJ) announced that the European Commission has approved Imaavy (nipocalimab) as an add-on therapy for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents.The targete ...